Afatinib (BIBW2992)

Catalog No.S1011

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Product Use Citation(34)

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTBwMEC1O|Ih|ryPNGD3eJVUSU6JRWK=
KASUMI-1NFjz[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEi5e4dKSzVyPUCuNFA6OTFizszNNUjsdFRVW0GQR1XS
HCC2218M{L3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rzTmlEPTB;MD6wNFk5PyEQvF2=NXLqVlk2W0GQR1XS
KARPAS-45MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\VOYcyUUN3ME2wMlAyPjdzIN88US=>M4fhd3NCVkeHUh?=
HSC-4M2G4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\ubWlEPTB;MD6wNVc1QCEQvF2=MVnTRW5ITVJ?
CHL-1NG\yTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTBwMEG4N|kh|ryPMkTLV2FPT0WU
KY821M2LlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTBwMEKwOkDPxE1?MmTWV2FPT0WU
NCI-N87MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fRbmlEPTB;MD6wNlc4OyEQvF2=M3nSS3NCVkeHUh?=
DOKNYflPWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTBwMEOxPVQh|ryPNGrSOppUSU6JRWK=
DSH1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTBwMEOzNVQh|ryPNYrjPY9yW0GQR1XS
MDA-MB-175-VIIM4XNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PuNGlEPTB;MD6wN|QyPiEQvF2=M4rDdHNCVkeHUh?=
NCI-H2170M3\EPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXQTWM2OD1yLkCzO|I5KM7:TR?=NFXubGxUSU6JRWK=
BT-474NXG2[XlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXMcplKSzVyPUCuNFQ6QDZizszNMYjTRW5ITVJ?
EFO-27M17ucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTBwMEWxPFIh|ryPNVfVUHBpW0GQR1XS
NCI-H720NHHxUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXGNZJtUUN3ME2wMlA2OzJ3IN88US=>MYDTRW5ITVJ?
PC-14NWHkNpNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTBwMEW2Olgh|ryPMWHTRW5ITVJ?
EC-GI-10Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwMEW5NVIh|ryPM3nERXNCVkeHUh?=
KYSE-450NX;VSlN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIe3R3BKSzVyPUCuNFU6PzhizszNNEPDT3BUSU6JRWK=
BPH-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LqXWlEPTB;MD6wOVk5QCEQvF2=NULMR|dLW0GQR1XS
NCI-H292MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfVW2NbUUN3ME2wMlA3ODlizszNMofkV2FPT0WU
H9NX65N495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTBwMEexN|Ih|ryPNXvy[WQzW0GQR1XS
NCI-H526M{LOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFyybldKSzVyPUCuNFc5OjNizszNMmDMV2FPT0WU
NCI-H1623NUX6cJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonaTWM2OD1yLkC4NFI2KM7:TR?=NIXEWVJUSU6JRWK=
KYSE-140MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTr[nJ3UUN3ME2wMlA5OzNizszNM{fZeHNCVkeHUh?=
Ca9-22MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLuTWM2OD1yLkC4N|U{KM7:TR?=NEflR5FUSU6JRWK=
AU565NIS1SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjSPZZ5UUN3ME2wMlA5PTB2IN88US=>NIHzenBUSU6JRWK=
ZR-75-30M2nOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3rTXNKSzVyPUCuNFk2PDVizszNMVLTRW5ITVJ?
NCI-H1770NGraU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXqxXmJuUUN3ME2wMlExOjhizszNNEXiXphUSU6JRWK=
LB2241-RCCM3XJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;lT5g6UUN3ME2wMlExQDh2IN88US=>M37Q[nNCVkeHUh?=
CAL-39MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTBwMUG3PVIh|ryPNYGwVZl4W0GQR1XS
UACC-893M4PtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2T3cGlEPTB;MD6xNVg5PSEQvF2=M{LaOXNCVkeHUh?=
LU-65NU[wdpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHewb5FKSzVyPUCuNVI3OzNizszNNVu5RVZXW0GQR1XS
HNNX31U4FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTBwMUOwO|ch|ryPNGnFS21USU6JRWK=
TI-73NX;v[Vk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zQemlEPTB;MD6xOFcyPSEQvF2=MWTTRW5ITVJ?
KU812M37IRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTBwMUW0OVYh|ryPNX72XVY{W0GQR1XS
SW13NWDEVpJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHmxPHZKSzVyPUCuNVYzOTZizszNNHvFcpVUSU6JRWK=
BB30-HNCNWfw[ndXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1KyUGlEPTB;MD6xOlU4PiEQvF2=NH;GV45USU6JRWK=
HSC-2MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLHTWM2OD1yLkG2PFM4KM7:TR?=M{XxV3NCVkeHUh?=
BV-173M{LkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnPOm9PUUN3ME2wMlE4PTl4IN88US=>MYrTRW5ITVJ?
CAL-27NU\iXZZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVK3c2hwUUN3ME2wMlE4PjN4IN88US=>NVSx[m9HW0GQR1XS
SBC-1NEHUNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3njcWlEPTB;MD6xPFk2QSEQvF2=M1LoUnNCVkeHUh?=
CAL-33MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLWTWM2OD1yLkKwNVg1KM7:TR?=NHjuRZBUSU6JRWK=
NCI-H209Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLyTWM2OD1yLkKwOFYh|ryPMljiV2FPT0WU
COR-L105NFHUVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPhZnlKSzVyPUCuNlExQDRizszNM1v5cnNCVkeHUh?=
HSC-3MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzhdG5KSzVyPUCuNlEyQThizszNMo\BV2FPT0WU
NCI-H69NHG3PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrCbpNKSzVyPUCuNlE1PTFizszNMW\TRW5ITVJ?
MOLT-13M12yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHznOVZKSzVyPUCuNlM6PzVizszNM1PLSHNCVkeHUh?=
ML-2MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPhTWM2OD1yLkK0PFAzKM7:TR?=NITZcXlUSU6JRWK=
IGROV-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4W0O2lEPTB;MD6yOVk2OiEQvF2=NEHPOFRUSU6JRWK=
TK10MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfpTWM2OD1yLkK2O|M5KM7:TR?=M321XnNCVkeHUh?=
EoL-1-cellNGS5PFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlO5TWM2OD1yLkK2PFkzKM7:TR?=NYTORnV2W0GQR1XS
HO-1-N-1NHrxTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;tUGJIUUN3ME2wMlI4QDV|IN88US=>MX\TRW5ITVJ?
BHYNGX0fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGj1emJKSzVyPUCuNlg3PTVizszNMWPTRW5ITVJ?
LU-139NU\0Z|lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LpSWlEPTB;MD6zNFUyKM7:TR?=MUTTRW5ITVJ?
23132-87Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHjWIp[UUN3ME2wMlMyQTJ|IN88US=>NH;HV4ZUSU6JRWK=
ACHNM4DVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M324XmlEPTB;MD6zNVk6PCEQvF2=NEjCWWdUSU6JRWK=
DoTc2-4510MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHWeYxDUUN3ME2wMlMzOjF7IN88US=>M3GwV3NCVkeHUh?=
BB65-RCCMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nEW2lEPTB;MD6zOFU6OyEQvF2=MXnTRW5ITVJ?
HLENYK1N2EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HjXmlEPTB;MD6zOVA1PiEQvF2=MXzTRW5ITVJ?
HCC1419MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLxZWZKSzVyPUCuN|Y1ODhizszNNV32eolmW0GQR1XS
A388M3rhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HZ[2lEPTB;MD6zOlg2PyEQvF2=NFW0XYhUSU6JRWK=
NUGC-3MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLJT4VKSzVyPUCuN|g{PzNizszNNWHDPW06W0GQR1XS
KYSE-180NVS4e|Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTBwM{mwPFkh|ryPMoexV2FPT0WU
TE-6NV[0SXB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTBwNECyOFYh|ryPMmTFV2FPT0WU
A498M{HpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVK0VGlwUUN3ME2wMlQxPjd2IN88US=>MVPTRW5ITVJ?
NCI-H1648M2jlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1e5W2lEPTB;MD60OFE5OiEQvF2=NYPpR2N7W0GQR1XS
DU-145NX3SZY5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTDc3Q{UUN3ME2wMlQ1QDN|IN88US=>MVvTRW5ITVJ?
CW-2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjNZ4VkUUN3ME2wMlQ3QTF2IN88US=>Mo[5V2FPT0WU
A431NVryZ5oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3TTWM2OD1yLkS4NlM{KM7:TR?=MmnFV2FPT0WU
SASMmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTBwNEizPVgh|ryPNHP6eHZUSU6JRWK=
NCI-H2126MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTBwNUG5NlYh|ryPNUHrfoh3W0GQR1XS
NCI-H358NX;6cJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\DXG5YUUN3ME2wMlU{OjFizszNNGXi[IRUSU6JRWK=
FADUNULMWoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTBwNUS0NFQh|ryPM3nWWHNCVkeHUh?=
ACNNXXMU4tRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4r4emlEPTB;MD61OVA6PCEQvF2=M1;GdXNCVkeHUh?=
HCC70NXPMbZdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPCO2pyUUN3ME2wMlU4PjZzIN88US=>MVjTRW5ITVJ?
NCI-H1838MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIC1blZKSzVyPUCuOlAzQTlizszNMV3TRW5ITVJ?
CAL-54MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkX5TWM2OD1yLk[xOlIyKM7:TR?=MnzpV2FPT0WU
NCI-H1975MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTqUXdKSzVyPUCuOlE4OjhizszNNVzBN5E5W0GQR1XS
COR-L88M{XLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHLVXh1UUN3ME2wMlY1OTF|IN88US=>MWLTRW5ITVJ?
CTV-1MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTBwNkSzPVIh|ryPNHm3WppUSU6JRWK=
EW-18NF3XPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPjTWM2OD1yLk[4Olk5KM7:TR?=MYnTRW5ITVJ?
HCC1806M{XDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWSyWmJQUUN3ME2wMlY6PjZ4IN88US=>MlXMV2FPT0WU
HuP-T4NYn4fG9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTBwNkm3OkDPxE1?MU\TRW5ITVJ?
MDA-MB-361NUHzemVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjPOYIyUUN3ME2wMlczPjZ{IN88US=>MV;TRW5ITVJ?
NCI-H1573MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjoSoNLUUN3ME2wMlc{PjNizszNNF;aWIZUSU6JRWK=
KU-19-19NGXIcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTBwN{e0OlQh|ryPNX\qSFVSW0GQR1XS
COLO-678NYP6bodjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUe4OlNSUUN3ME2wMlgxQDN2IN88US=>MYLTRW5ITVJ?
C-33-AMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoW1TWM2OD1yLkixNlk4KM7:TR?=MlfuV2FPT0WU
Calu-3M37HSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYezVm53UUN3ME2wMlgyPDN2IN88US=>NIHpSW1USU6JRWK=
AGSM4XaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\DZWY{UUN3ME2wMlg{PjR6IN88US=>NVHqemljW0GQR1XS
SCC-25NXvUVpZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoT5TWM2OD1yLki0NVcyKM7:TR?=MojrV2FPT0WU
JVM-2M2fucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfhTWM2OD1yLki4Nlk6KM7:TR?=NEHIZmFUSU6JRWK=
HCE-TMnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;hWpBKSzVyPUCuPFg1OjhizszNNXTlS5R1W0GQR1XS
ES4MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fNWWlEPTB;MD65O|g{PiEQvF2=MYPTRW5ITVJ?
EKVXMoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn[0TWM2OD1zLkCxNFY1KM7:TR?=M2HyXnNCVkeHUh?=
D-542MGNX;teFNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTFwMEGwOlQh|ryPMVrTRW5ITVJ?
SW1116MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jv[2lEPTB;MT6wNVI5PyEQvF2=MXjTRW5ITVJ?
5637MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjJZnZKSzVyPUGuNFE2OSEQvF2=NUnTfINWW0GQR1XS
HT-1376NVyyclA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV20O2ltUUN3ME2xMlAyPTF|IN88US=>NH23OYdUSU6JRWK=
NB69NGjZeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTFwMEK5OFUh|ryPM3Lq[XNCVkeHUh?=
YKG-1MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;DXG9KSzVyPUGuNFU1OTlizszNM2Ww[nNCVkeHUh?=
EW-3NHW3cI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\2TWM2OD1zLkC3PFg{KM7:TR?=NF7rRmNUSU6JRWK=
GCIYMkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ewSGlEPTB;MT6wPFExPCEQvF2=NVnud|NZW0GQR1XS
SK-MES-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13ZcGlEPTB;MT6xNVQ5PyEQvF2=M36yOHNCVkeHUh?=
PANC-08-13MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTFwMU[0NVYh|ryPNV\YWIxJW0GQR1XS
SK-NEP-1M4DSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PEfmlEPTB;MT6xO|UyOyEQvF2=Mmj3V2FPT0WU
SW954NIfhfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfJT2hKSzVyPUGuNlAzOTRizszNM3jSO3NCVkeHUh?=
NCI-SNU-5NEG3fI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzONGhKSzVyPUGuNlM6KM7:TR?=NILOUlBUSU6JRWK=
SW48M3HUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn73TWM2OD1zLkK1OFMzKM7:TR?=NWnieFNoW0GQR1XS
HT-3M2TDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTFwMki3OVMh|ryPMVHTRW5ITVJ?
ETK-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XWOGlEPTB;MT6zO|Q2PiEQvF2=NUfGNoprW0GQR1XS
SCC-15M1jwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTFwM{m0OVEh|ryPMnKwV2FPT0WU
DU-4475M{DPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jLVGlEPTB;MT60NFEzOSEQvF2=NGDPeY9USU6JRWK=
NB5NXHDR4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzZZ2xKSzVyPUGuOFE{OTdizszNMXjTRW5ITVJ?
CFPAC-1M3nxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTFwNEK0PVMh|ryPNHTw[oRUSU6JRWK=
NCI-H630MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mor3TWM2OD1zLkS1OVgzKM7:TR?=MUXTRW5ITVJ?
NCI-H82Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzrS|hKSzVyPUGuOVQxODZizszNNIHPdFhUSU6JRWK=
ECC10NVrDeo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTFwNUWzOlkh|ryPMXnTRW5ITVJ?
K5Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fUTWlEPTB;MT61PFM2PyEQvF2=Mk\BV2FPT0WU
ME-180MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TSRmlEPTB;MT62NVA6PiEQvF2=MmDtV2FPT0WU
KYSE-410NXToVZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2O1OmlEPTB;MT62OVY4OiEQvF2=MXjTRW5ITVJ?
G-401MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXvfJZKSzVyPUGuOlc1OTNizszNNYXoSYR4W0GQR1XS
TGBC24TKBNELMSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnWWnlKSzVyPUGuOlgzOyEQvF2=NV7DdopnW0GQR1XS
Detroit562MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkj3TWM2OD1zLkewNVUzKM7:TR?=MUDTRW5ITVJ?
OE19MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFr0ephKSzVyPUGuO|E2OTJizszNNEfscVFUSU6JRWK=
CAKI-1NIPjOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Px[WlEPTB;MT63PFIyOSEQvF2=NFTVeJpUSU6JRWK=
TE-12M2\mS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTFwOEC0NVQh|ryPNUPqcFhKW0GQR1XS
NCI-H1666NYPMOZNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfkS5FQUUN3ME2xMlgxQTR6IN88US=>MYTTRW5ITVJ?
TE-1M4rVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTFwOEG0O|Uh|ryPM4nYWHNCVkeHUh?=
CAL-12TNIjuUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYP1cWZWUUN3ME2xMlg5QTR3IN88US=>NXzwUXdkW0GQR1XS
TE-8NILsNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTFwOUGzO|ch|ryPNHPySpZUSU6JRWK=
KYSE-270M33keGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorpTWM2OD1{LkCyO|MzKM7:TR?=MVHTRW5ITVJ?
GMS-10NEfoZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHntb3NKSzVyPUKuNFM2OTdizszNMX\TRW5ITVJ?
A2780MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjFTWM2OD1{LkC2Nlk1KM7:TR?=M{j0RnNCVkeHUh?=
OMC-1M1jIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;Ob2lEPTB;Mj6wPFE3QSEQvF2=MlfnV2FPT0WU
LoVoMn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;BTWM2OD1{LkGwO|k4KM7:TR?=MXnTRW5ITVJ?
PANC-03-27NGXUe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlL3TWM2OD1{LkG2OlMyKM7:TR?=MUXTRW5ITVJ?
MDA-MB-157NGHzbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfNdnBKSzVyPUKuNlE5OjhizszNNYfDcZpyW0GQR1XS
CaR-1Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTJwMkiyPFEh|ryPM3XBN3NCVkeHUh?=
769-PMlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\HV2lEPTB;Mj6yPVA{PyEQvF2=Mn3ZV2FPT0WU
NB7NEnld2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HqU2lEPTB;Mj6yPVY4PiEQvF2=MWLTRW5ITVJ?
MKN7MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTlXHhKSzVyPUKuN|U{OzVizszNM{XHXnNCVkeHUh?=
NCI-H1048MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVK5PWFSUUN3ME2yMlQ6OTV6IN88US=>MXPTRW5ITVJ?
RCM-1M2HYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHmZnFKSzVyPUKuOVI6OzhizszNMUHTRW5ITVJ?
HT55M{\vWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnre|dKSzVyPUKuOVc{QCEQvF2=NYD2co97W0GQR1XS
HCC1569M3z3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLZc5BTUUN3ME2yMlU5Ojl5IN88US=>NXfzV3hkW0GQR1XS
LXF-289MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPpbllKSzVyPUKuOlM2PjVizszNNVLzfW1wW0GQR1XS
OVCAR-3MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWq0dIlQUUN3ME2yMlY4OTZ5IN88US=>NUXYOVl3W0GQR1XS
TE-10MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTJwNkiwO|gh|ryPMX\TRW5ITVJ?
SNU-C2BMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jxTWlEPTB;Mj62PFYyPiEQvF2=M4LZSHNCVkeHUh?=
LB1047-RCCM{nRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7lUplKSzVyPUKuO|Q5QDhizszNMXHTRW5ITVJ?
SN12CNEDqUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJwOUG5OlQh|ryPMWrTRW5ITVJ?
786-0MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILQXotKSzVyPUOuNFY1ODhizszNM4O1cXNCVkeHUh?=
HT-29MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XiN2lEPTB;Mz6wO|MxQSEQvF2=NUWxdGJHW0GQR1XS
RPMI-7951MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTNwMEe1PUDPxE1?M{SybXNCVkeHUh?=
NBsusSRNFv1cZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHOTWM2OD1|LkG4NlU1KM7:TR?=MlO5V2FPT0WU
NKM-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nFdGlEPTB;Mz6xPFc1PCEQvF2=MkDIV2FPT0WU
Capan-2M2jzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmmwTWM2OD1|LkS2PFc2KM7:TR?=MXHTRW5ITVJ?
MKN1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7VSolKSzVyPUOuOFcyODhizszNNGDPNmJUSU6JRWK=
OAW-42MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTNwNUCwNlYh|ryPMoDkV2FPT0WU
SKG-IIIaMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjw[4lmUUN3ME2zMlUzOjN5IN88US=>M1ryfXNCVkeHUh?=
no-11NHzYfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[ySZNLUUN3ME2zMlU{PTZ2IN88US=>MlK4V2FPT0WU
NYM4\Dfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXENplxUUN3ME2zMlU{PjV3IN88US=>M4C0enNCVkeHUh?=
HEC-1MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLlTWM2OD1|LkW4PVUh|ryPMoPUV2FPT0WU
NCI-H441MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7CV|RJUUN3ME2zMlU6QDRzIN88US=>MmfxV2FPT0WU
NCI-H2009NWfCZmdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\kOIRKSzVyPUOuOlEzOTZizszNMmmwV2FPT0WU
T47DNFvuVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW[4U|lzUUN3ME2zMlYzOjF5IN88US=>MmTLV2FPT0WU
SNU-449MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDOTWM2OD1|Lk[1PFI3KM7:TR?=NXjoR41xW0GQR1XS
NCI-SNU-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfsTWM2OD1|Lk[5O|M2KM7:TR?=NGqzUYJUSU6JRWK=
BT-20M37HfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PudWlEPTB;Mz62PVc6PSEQvF2=M3zrSHNCVkeHUh?=
LS-123M{DYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYn3WVZ[UUN3ME2zMlc1Ojh2IN88US=>NUfObo1mW0GQR1XS
8305CMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUL4bIhWUUN3ME2zMlc2QTFzIN88US=>NU[zNZJxW0GQR1XS
OCUB-MNUfTdYhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTNwN{[xPFch|ryPNXHvdodSW0GQR1XS
KOSC-2M1\Ebmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTNwOEO0OVEh|ryPMlLTV2FPT0WU
NCI-H1693MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTNwOESxPFEh|ryPNH74bIVUSU6JRWK=
TE-9NWe3blY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTNwOESzPFIh|ryPMUfTRW5ITVJ?
MV-4-11NYCzVFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrrUY5PUUN3ME2zMlg4QTl2IN88US=>NWfZbY51W0GQR1XS
GAMGNFHxXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XpcWlEPTB;Mz65NVMyPCEQvF2=MXfTRW5ITVJ?
KNS-62M3vuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3X2U2lEPTB;Mz65OFc{OSEQvF2=M{XuWXNCVkeHUh?=
MC116MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTn[I5jUUN3ME2zMlk2PDh7IN88US=>NFP1U29USU6JRWK=
647-VMnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzFTWM2OD1|Lkm4OFUzKM7:TR?=NGn6VGJUSU6JRWK=
U-87-MGNWj3clRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTRwMUC0PFEh|ryPMXrTRW5ITVJ?
RPMI-8226M4S1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHr3ZVBKSzVyPUSuNVE3OzFizszNMYrTRW5ITVJ?
SW1417NXrYfVdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrYTWM2OD12LkGyNVQ4KM7:TR?=MYnTRW5ITVJ?
LAMA-84Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTRwMUewNkDPxE1?NUTtfFlUW0GQR1XS
LS-513M{LTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjjVHZkUUN3ME20MlMyOjF5IN88US=>NIDTeWVUSU6JRWK=
KLEMnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\ST|NKSzVyPUSuOFA5OTlizszNM{H6[3NCVkeHUh?=
HCT-116NVHtS4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTRwNEGwNFch|ryPM1\iVHNCVkeHUh?=
EPLC-272HNFjpcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:4TWM2OD12LkSxOVM{KM7:TR?=MYfTRW5ITVJ?
KS-1M3vWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTRwNUC4PFkh|ryPNF\3VWxUSU6JRWK=
HT-1197MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7VSINKSzVyPUSuOVI3PjlizszNMX;TRW5ITVJ?
LCLC-97TM1NYfpR3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTRwNUO2PFYh|ryPMnznV2FPT0WU
ES5M2LL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXoVJdKSzVyPUSuPFM4OjNizszNMnG1V2FPT0WU
CTB-1MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzXTWM2OD12Lki0PFgh|ryPMX\TRW5ITVJ?
HL-60MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTRwOE[2NVEh|ryPM4[yZnNCVkeHUh?=
VM-CUB-1NGPuWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTRwOE[4NVkh|ryPNIHKfFJUSU6JRWK=
MEG-01MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\2W49CUUN3ME20Mlk6PDB|IN88US=>M4Lkb3NCVkeHUh?=
KYSE-520NGTmVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XQXWlEPTB;NT6yNFg{QSEQvF2=Mnr5V2FPT0WU
HuO-3N1MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHGyWVlKSzVyPUWuNlQxPDNizszNMVrTRW5ITVJ?
SW620NHTlVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nUVWlEPTB;NT6yOFk3PCEQvF2=M4XwdnNCVkeHUh?=
U031NULBe2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTVwMkW0NlQh|ryPMoe2V2FPT0WU
TE-5MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvBWGVKSzVyPUWuOFA5PSEQvF2=MWHTRW5ITVJ?
NCI-H747NVn6e3E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoqxTWM2OD13LkSyOFczKM7:TR?=NEjjOGlUSU6JRWK=
MG-63NFHwVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHHeJJKSzVyPUWuOFg4PjJizszNNEK2VGxUSU6JRWK=
HC-1Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\sV2ZnUUN3ME21MlUyQDN7IN88US=>MkLOV2FPT0WU
HCC2998MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13GeGlEPTB;NT61NlYyPSEQvF2=MU\TRW5ITVJ?
NTERA-S-cl-D1NHztT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTVwNUS1N|ch|ryPM3\GZ3NCVkeHUh?=
KINGS-1NFXtNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVThdItDUUN3ME21MlYxQTR2IN88US=>M2DPXHNCVkeHUh?=
D-423MGMorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTVwNkG3NFUh|ryPM2rOVnNCVkeHUh?=
SW962NGPi[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfOTWM2OD13Lk[yNFMzKM7:TR?=NHq0VmVUSU6JRWK=
LOXIMVIMkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXSTWM2OD13Lk[zPFc{KM7:TR?=NILaT4NUSU6JRWK=
LS-411NNFLjTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfpN3FKSzVyPUWuO|k1PDFizszNNXvMZW1KW0GQR1XS
NCI-H2291M3jyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mni4TWM2OD13Lkm4PVQ{KM7:TR?=NEntUpdUSU6JRWK=
A549NFnKc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmS0TWM2OD14LkGyOVU{KM7:TR?=MX3TRW5ITVJ?
LS-1034MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;QWGlEPTB;Nj6yNFcxPiEQvF2=M{GzXnNCVkeHUh?=
NB14M3vBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvRVHdKSzVyPU[uOFM5OzZizszNMXLTRW5ITVJ?
NCI-H1299NIX2SopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHyzRpVKSzVyPU[uOlMyPzFizszNM1HYbnNCVkeHUh?=
BT-549MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fxbGlEPTB;Nj62Olg5QSEQvF2=NXvkVpo4W0GQR1XS
J-RT3-T3-5NInKcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTZwOE[5JO69VQ>?MlPPV2FPT0WU
SW756NHnjclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPFPWhKSzVyPU[uPVEyPzZizszNM1z3XHNCVkeHUh?=
DJM-1Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXsVoRKSzVyPU[uPVIxOTJizszNNUjteZA6W0GQR1XS
GP5dNGfDV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTFTWM2OD14Lkm3N|k1KM7:TR?=MUTTRW5ITVJ?
MOLT-4NV3n[ndFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7VTWRKSzVyPUeuNFIyOzVizszNMoT5V2FPT0WU
NCI-H28NEHXb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33oW2lEPTB;Nz6xOlQxPSEQvF2=NVHQUXRGW0GQR1XS
MN-60NXzT[YxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXISXVDUUN3ME23MlI5ODh7IN88US=>MV3TRW5ITVJ?
RMG-IMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnVTIJwUUN3ME23MlM6Ojl4IN88US=>MUjTRW5ITVJ?
COLO-800Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPyV3lxUUN3ME23MlQyPDR4IN88US=>MXTTRW5ITVJ?
DBM3nVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXLbXRyUUN3ME23MlYyODB3IN88US=>MlTSV2FPT0WU
Ca-SkiM1HQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVX4Vm9nUUN3ME23MlY1OjV7IN88US=>NXXtZWhsW0GQR1XS
HELNWHVcnZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTdwN{GyNFMh|ryPNYnHbmlVW0GQR1XS
NH-12M4L5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\Lb2lEPTB;Nz63NlgxQCEQvF2=MV3TRW5ITVJ?
LB373-MEL-DNV3x[3cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXBfJVKSzVyPUeuO|Y4PzFizszNNFrJc|NUSU6JRWK=
SW900NVLUcWY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nIdmlEPTB;Nz64NlEzOSEQvF2=NW\GVZdGW0GQR1XS
JVM-3NWiw[|BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTdwOEm1PVkh|ryPM4rtSHNCVkeHUh?=
OAW-28MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTdwOUS1O|gh|ryPMWrTRW5ITVJ?
KURAMOCHIMl3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoixTWM2OD15Lkm0PFEyKM7:TR?=M4PHXHNCVkeHUh?=
BE-13NYDO[YV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfETWM2OD15Lkm4NVEzKM7:TR?=M3nlbXNCVkeHUh?=
VMRC-RCZNVf1OIptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3W4WGlEPTB;OD6wNVY6PyEQvF2=NF[1b4xUSU6JRWK=
NCI-H727NWnUTpVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRThwMUC0NkDPxE1?MYfTRW5ITVJ?
SW1710NY\yd|RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jve2lEPTB;OD6xPFUyPSEQvF2=NGHpbo9USU6JRWK=
D-502MGNHnMVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRThwMkmyPFIh|ryPMkDJV2FPT0WU
NCI-H1993NHvMeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;Vd|RKSzVyPUiuN|M3OzFizszNNEi0SItUSU6JRWK=
SCC-4MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF6xeXBKSzVyPUiuOFQxPTlizszNMnX2V2FPT0WU
HAL-01NYezZVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1Hw[GlEPTB;OD61NVkyKM7:TR?=NWDLRYloW0GQR1XS
GT3TKBNFnEUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRThwNke5OlQh|ryPNUDZV2RUW0GQR1XS
SK-OV-3NF75NIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlOyTWM2OD16LkexN|I6KM7:TR?=NH\pS2FUSU6JRWK=
COLO-829NXyzZnpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTqXItKSzVyPUiuPFA6PzZizszNMYTTRW5ITVJ?
OCI-AML2MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRThwOUW0PFEh|ryPM{W4U3NCVkeHUh?=
OS-RC-2M2[xZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{m2W2lEPTB;OT6wNlE6KM7:TR?=MYrTRW5ITVJ?
BFTC-909M17Bd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDyRnl7UUN3ME25MlA3Pzl7IN88US=>MVXTRW5ITVJ?
EW-11NUfWXIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTlwMUe2OVMh|ryPM3jKPHNCVkeHUh?=
HCE-4NH24fFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTlwMkG1OVgh|ryPMn\5V2FPT0WU
BALL-1MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTlwMkG5NFch|ryPM3TxSXNCVkeHUh?=
SF539M3HZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PGSWlEPTB;OT6yN|U3OiEQvF2=M{jYd3NCVkeHUh?=
CAMA-1NYK1TmJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjpTWM2OD17LkK4NVI5KM7:TR?=Mnn6V2FPT0WU
C32MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{m5[mlEPTB;OT6zN|A3PCEQvF2=M{nZ[XNCVkeHUh?=
NCI-H1703NE\6OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEX0NnJKSzVyPUmuN|Q{PzVizszNMYfTRW5ITVJ?
NCI-H1650NXL2XZRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTlwNkC5OFYh|ryPMmnLV2FPT0WU
NCI-H1563MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvrTWM2OD17Lke2NFMyKM7:TR?=NWjZbmEzW0GQR1XS
CAL-85-1NV\SO|J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTlwOEezPFMh|ryPNUDTVmRXW0GQR1XS
UM-UC-3M3\2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3OzZ2lEPTB;OT65OVA{KM7:TR?=NEHXNpBUSU6JRWK=
BxPC-3MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jnemlEPTB;MUCuNFk4OiEQvF2=MnzXV2FPT0WU
MHH-PREB-1MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTHTWM2OD1zMD6xPVk6KM7:TR?=NI\CcWdUSU6JRWK=
DELNWHjW3NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELNPIZKSzVyPUGwMlM6PDZizszNM1:0[3NCVkeHUh?=
HuCCT1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HNSWlEPTB;MUCuOlA{OyEQvF2=MmjMV2FPT0WU
OVCAR-4MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTFyLki4N|Uh|ryPM2jtSXNCVkeHUh?=
CAL-72NIexNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVy1NlNqUUN3ME2xNE46OzlzIN88US=>MkXhV2FPT0WU
HCC1954M3GwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fQZ2lEPTB;MUGuNFc2PCEQvF2=MWHTRW5ITVJ?
EFO-21MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfoUWNNUUN3ME2xNU4yODR3IN88US=>Mon0V2FPT0WU
FTC-133NXHGS|hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLs[4tIUUN3ME2xNU4yPDB5IN88US=>MVHTRW5ITVJ?
SK-MEL-24NVfjbpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrHTWM2OD1zMT6yN|Y3KM7:TR?=NHHuWW9USU6JRWK=
UACC-62NIrNcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3WyUGlEPTB;MUGuNlM3QCEQvF2=NICzRZBUSU6JRWK=
NCI-H650NYfYTVlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4W2WWlEPTB;MUGuNlQyQCEQvF2=MWXTRW5ITVJ?
ALL-POMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDrT5N1UUN3ME2xNU4zPTF{IN88US=>NYez[FZoW0GQR1XS
T84M3znV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIS4bVVKSzVyPUGxMlM6ODdizszNMVfTRW5ITVJ?
IST-MEL1NFfSdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7uTWM2OD1zMT60OVU6KM7:TR?=MlvUV2FPT0WU
SW626NV\2OWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDPPZhNUUN3ME2xNU42PzV3IN88US=>NGjrOmxUSU6JRWK=
RPMI-2650M4DGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTFzLkW4PFUh|ryPNGq4O|NUSU6JRWK=
MC-IXCNVLpW49VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;xWmZrUUN3ME2xNU43PzJ6IN88US=>M4DwSHNCVkeHUh?=
HOP-62NWnzRYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYH3[YdvUUN3ME2xNU43PzZ2IN88US=>Ml3rV2FPT0WU
NOS-1NWjhcFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTNbIVKSzVyPUGxMlcyODlizszNNVPUTWNYW0GQR1XS
SW1573NHzBUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTFzLkeyPVUh|ryPMXPTRW5ITVJ?
WM-115M3vURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4focGlEPTB;MUGuO|U5QCEQvF2=NV7VPIF3W0GQR1XS
HuO9NVL2XVNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIW2N5NKSzVyPUGxMlg4PzRizszNMX7TRW5ITVJ?
YAPCMknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nzWmlEPTB;MUGuPVI2QSEQvF2=NWP4R2ZxW0GQR1XS
MDA-MB-453NFS0VYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFG3TmxKSzVyPUGxMlk2OTVizszNNXX4RpFqW0GQR1XS
NCI-H596MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3X4XmlEPTB;MUKuNFM3QSEQvF2=NHnEbHJUSU6JRWK=
A172MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\aTWM2OD1zMj6wO|k5KM7:TR?=M{\j[3NCVkeHUh?=
RS4-11MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTF{LkG3NlUh|ryPM3rjWnNCVkeHUh?=
HCC1937MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTF{Lke1OlQh|ryPMYLTRW5ITVJ?
SW837MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTF{LkmwNlgh|ryPM{mwRnNCVkeHUh?=
NMC-G1M1LHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvKTWM2OD1zMj65NlM1KM7:TR?=MXHTRW5ITVJ?
PFSK-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLqbFZKSzVyPUGzMlA3KM7:TR?=NWn6WllEW0GQR1XS
DBTRG-05MGNHT4WJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P6cGlEPTB;MUOuNFY{OiEQvF2=NVnZVVZpW0GQR1XS
SK-UT-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1[xTWlEPTB;MUOuNVA5OyEQvF2=NYrzd4c3W0GQR1XS
OVCAR-5NX7QcGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLYR|lKSzVyPUGzMlE2QTNizszNMkLnV2FPT0WU
8505CMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3ftWGlEPTB;MUOuNlA3PyEQvF2=NGjmUZhUSU6JRWK=
SK-MEL-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmK2TWM2OD1zMz63NVM2KM7:TR?=NX;X[2tbW0GQR1XS
LK-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnVcVRKSzVyPUGzMlc3OzlizszNMYPTRW5ITVJ?
OE33M1\zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLVXldUUUN3ME2xN{44QDZizszNMWnTRW5ITVJ?
Ramos-2G6-4C10M{LoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTF2LkCyNFIh|ryPMVfTRW5ITVJ?
EW-13NHi1emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjseG5KSzVyPUG0MlA{PTJizszNNF\3O|JUSU6JRWK=
NCI-H1793MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzxPXdKSzVyPUG0MlIxQDdizszNMXrTRW5ITVJ?
BHT-101NYe2V2lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnroTWM2OD1zND6yOFEh|ryPMYLTRW5ITVJ?
RKONH3Pbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TVPWlEPTB;MUSuOVA4PSEQvF2=NVvRNGU3W0GQR1XS
NEC8M{PaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vJcGlEPTB;MUSuOVQ4OiEQvF2=M13WcnNCVkeHUh?=
PANC-10-05NHO1O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXsPVVKUUN3ME2xOE43OjR5IN88US=>NY\PdYVJW0GQR1XS
NCI-H2030MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HFSWlEPTB;MUSuOlQ1QCEQvF2=NX7rbm56W0GQR1XS
C2BBe1NGPUXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPRVYJCUUN3ME2xOE44PjRizszNMoH6V2FPT0WU
EM-2NYC4NpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mom3TWM2OD1zND64OVc3KM7:TR?=NHHkd2dUSU6JRWK=
HCC1395NXnnXZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnS5TWM2OD1zND65N|M5KM7:TR?=MV\TRW5ITVJ?
A2058NF:3fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HFSGlEPTB;MUWuNFQxQSEQvF2=NV;YZ4pqW0GQR1XS
SW1463NGnhWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjTTWM2OD1zNT6wOFg2KM7:TR?=NEK2Z25USU6JRWK=
J82MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Xq[WlEPTB;MUWuNFU4KM7:TR?=M3jBO3NCVkeHUh?=
CAL-120MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{W3UWlEPTB;MUWuNVQ1PyEQvF2=MoCyV2FPT0WU
COLO-824NXrLRlRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3W0T2lEPTB;MUWuNVU4QSEQvF2=MWDTRW5ITVJ?
LNCaP-Clone-FGCM1niR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXxN|VKSzVyPUG1MlQzPDhizszNNHLYbllUSU6JRWK=
CP66-MELNXe2bHA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTF3LkS2PFgh|ryPNVzJTZV3W0GQR1XS
OC-314MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTF3LkS3NVQh|ryPMn3oV2FPT0WU
OVCAR-8M2XhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PnUmlEPTB;MUWuPFg3OSEQvF2=M3vNeHNCVkeHUh?=
MFE-280NXvVeo5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfLTWM2OD1zNj6wOFg5KM7:TR?=MVLTRW5ITVJ?
MHH-NB-11MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TVe2lEPTB;MU[uNFg{QSEQvF2=NWS3e2ZsW0GQR1XS
SW1990NVr2RWlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTF4LkG3OVUh|ryPMWjTRW5ITVJ?
U-266M1HybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jsb2lEPTB;MU[uNlI6QSEQvF2=MXfTRW5ITVJ?
MFM-223NFnIOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF4LkO5OlUh|ryPMUTTRW5ITVJ?
L-363M2[3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTF4LkS1O|ch|ryPMXPTRW5ITVJ?
MCF7NUHkOnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTF4LkS3NlMh|ryPMV7TRW5ITVJ?
SK-MEL-3MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjycpVKSzVyPUG2MlQ4QDdizszNMUfTRW5ITVJ?
HHNXz0SVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXoeWtKSzVyPUG2MlUyPjJizszNMV7TRW5ITVJ?
no-10MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEKxTItKSzVyPUG2MlY{PDNizszNNFHlW2lUSU6JRWK=
HuP-T3NV3OVVVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTF4Lk[1O|Yh|ryPMUPTRW5ITVJ?
QIMR-WILMkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPpTWM2OD1zNj63NVA2KM7:TR?=MYLTRW5ITVJ?
NCI-H1092MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHP3eHNKSzVyPUG2Mlg{OTZizszNNHKxZ2hUSU6JRWK=
MZ2-MELNHntd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrJTWM2OD1zNj64OFA{KM7:TR?=M{DsRXNCVkeHUh?=
ES3MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXr6UoJNUUN3ME2xOk46OTN2IN88US=>MXLTRW5ITVJ?
COLO-684MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYX5NFRtUUN3ME2xOk46PDd5IN88US=>M1TtV3NCVkeHUh?=
NCI-H661NGnIU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfvTWM2OD1zNj65Olk1KM7:TR?=M4LjfnNCVkeHUh?=
CP50-MEL-BMlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4W1XWlEPTB;MUeuNFM1OyEQvF2=NV;HPJJ5W0GQR1XS
NCI-H2405M3y0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTF5LkG5O|Qh|ryPMo\YV2FPT0WU
U-2-OSMkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\DbGlEPTB;MUeuOVMxPyEQvF2=NX3OXVNPW0GQR1XS
RERF-LC-MSM3jiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S1SmlEPTB;MUeuOVUxQCEQvF2=MX;TRW5ITVJ?
NCI-H2342M1yzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTF5LkW1O{DPxE1?NH;KO3FUSU6JRWK=
ES8Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml31TWM2OD1zNz62NFg4KM7:TR?=MoTPV2FPT0WU
MOLT-16NVr1To9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1e2UWlEPTB;MUeuPFk{PCEQvF2=NWHncYVPW0GQR1XS
RH-18MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfuTWM2OD1zOD6wNFM2KM7:TR?=MYnTRW5ITVJ?
D-283MEDM3Tid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTCOZIxUUN3ME2xPE4xODh6IN88US=>M4nXRXNCVkeHUh?=
RCC10RGBNWTZclViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXOTWM2OD1zOD6wOVU6KM7:TR?=NWfVZm4zW0GQR1XS
NCI-H1437M2XqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTF6LkG2OFEh|ryPNUe3fHg3W0GQR1XS
SW982M4nDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnpNFhKSzVyPUG4MlI3PzFizszNMmrIV2FPT0WU
IST-MES1NEnkZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjPUXRYUUN3ME2xPE41PDJ6IN88US=>NY\lRpN7W0GQR1XS
A704NXO2ZlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPXTWl2UUN3ME2xPE41PzV|IN88US=>M1;FTnNCVkeHUh?=
ESS-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TBVGlEPTB;MUiuOVIxPSEQvF2=NILPcG5USU6JRWK=
SCHMoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn[xTWM2OD1zOD62OFU3KM7:TR?=M4nLbnNCVkeHUh?=
COLO-320-HSRMlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXK5bWtJUUN3ME2xPE44PDZizszNNHf1WWxUSU6JRWK=
Mo-TNFXmUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnQ[FdKSzVyPUG4MlgzODRizszNNVGy[GZYW0GQR1XS
Saos-2NVzKS|kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTF7LkGxOlIh|ryPM1;ybXNCVkeHUh?=
SW684M3:xeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVqy[FhmUUN3ME2xPU4yOzJ4IN88US=>NXzYOmo2W0GQR1XS
KMOE-2NVTZeFJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTF7LkKyOFIh|ryPMknzV2FPT0WU
MMAC-SFNWHkTnp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHIb4s6UUN3ME2xPU4zPjB5IN88US=>NHnvXmdUSU6JRWK=
JARMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTWbGg5UUN3ME2xPU4zQTlizszNNXzUZncyW0GQR1XS
SK-MEL-28NV7PSVFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3sNW9KSzVyPUG5MlM{PjNizszNNGfHZlVUSU6JRWK=
KNS-81-FDMnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPFe3d2UUN3ME2xPU42PDZ6IN88US=>MlPUV2FPT0WU
ES7NIH1TIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvPUFQ2UUN3ME2xPU43Ojl{IN88US=>NUSwSZFwW0GQR1XS
AsPC-1NEDiVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPuTWM2OD1zOT62OFcyKM7:TR?=MX3TRW5ITVJ?
NCI-H1155MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;aNIJKSzVyPUG5MlczOzhizszNNYC4WZFkW0GQR1XS
KYSE-510M3LtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XoZ2lEPTB;MUmuPFc1QCEQvF2=Ml21V2FPT0WU
ES1MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTF7LkmyNVMh|ryPMlT1V2FPT0WU
PC-3M{HySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEK4S|FKSzVyPUG5Mlk3ODRizszNM3HNRnNCVkeHUh?=
GCTNUfZZ2JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzvTWM2OD1{MD6zNFI3KM7:TR?=MUnTRW5ITVJ?
KARPAS-299M2DNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PtVWlEPTB;MkCuN|QzOiEQvF2=Mm\CV2FPT0WU
DOHH-2MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3jTWM2OD1{MD61OFY{KM7:TR?=NV\ZSJJzW0GQR1XS
COLO-741M4PkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTJyLk[2JO69VQ>?NWX1WHAyW0GQR1XS
NCI-H1395M2CwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTJyLk[2PVch|ryPNUfkNHp[W0GQR1XS
HCC1187M2TNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGX2RlhKSzVyPUKwMlY4OzRizszNMnm3V2FPT0WU
BeckerNY\4cVE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELNbYpKSzVyPUKwMlczODFizszNM3TtVXNCVkeHUh?=
LU-134-AMlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjuXmJKSzVyPUKxMlExOjZizszNMUjTRW5ITVJ?
MKN45MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPud5hkUUN3ME2yNU4yPTVzIN88US=>NVnaXop1W0GQR1XS
LC-2-adMlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3KSodGUUN3ME2yNU4zPzJ7IN88US=>MkTmV2FPT0WU
EW-24MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnuSIJ{UUN3ME2yNU4{QTR3IN88US=>NXrncJMzW0GQR1XS
SK-N-ASNUTnNFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTJzLkiyO|Yh|ryPMX;TRW5ITVJ?
NCI-H2052NEjCNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTJzLki5OlMh|ryPMlj4V2FPT0WU
A4-FukMmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjLdXFKSzVyPUKyMlE1OTlizszNM3roSXNCVkeHUh?=
NB10M{\je2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn70TWM2OD1{Mj6yN|cyKM7:TR?=M1XmT3NCVkeHUh?=
CHP-212Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJ{LkOyNlIh|ryPNYjjVGVpW0GQR1XS
KM12MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HDTGlEPTB;MkKuN|U3KM7:TR?=NEPW[mlUSU6JRWK=
JEG-3Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjlTWM2OD1{Mj6zO|gh|ryPNUDPZpVrW0GQR1XS
LN-405M1PQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rwbWlEPTB;MkKuOVkyOyEQvF2=M2r0W3NCVkeHUh?=
HCT-15MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTJ{Lke0OFEh|ryPMXvTRW5ITVJ?
MLMAM1;CN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\GOplKSzVyPUKyMlc1PyEQvF2=MVHTRW5ITVJ?
GI-1MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;DTWM2OD1{Mj63OlU5KM7:TR?=NXvFfGZSW0GQR1XS
RT-112NV;lbZBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTibmdKSzVyPUKyMlg3OTZizszNNGW5VpFUSU6JRWK=
MPP-89MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTJ{Lki2OlEh|ryPNVHHU4l[W0GQR1XS
A3-KAWNGHCU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWX0d5dEUUN3ME2yN{4yODB|IN88US=>M1jxd3NCVkeHUh?=
KALS-1M2TpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnNcZFXUUN3ME2yN{4yPDF2IN88US=>NVzjdJI2W0GQR1XS
SF126NGryfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEn4U41KSzVyPUKzMlY6OjRizszNM{\IbXNCVkeHUh?=
SiHaM2r5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGC0UW1KSzVyPUKzMlk{OjdizszNNWPh[JJ1W0GQR1XS
MDA-MB-415Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTLRXFQUUN3ME2yN{46PDl7IN88US=>MVfTRW5ITVJ?
DaoyM3z1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrNfYk4UUN3ME2yOE4yOjZizszNM4fwc3NCVkeHUh?=
COR-L23MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17JUmlEPTB;MkSuNVc3PyEQvF2=NXfyVIloW0GQR1XS
KG-1M{nz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\PNGlEPTB;MkSuNVkzQCEQvF2=NHz4[WJUSU6JRWK=
L-428M3Pacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTJ2LkW3PVEh|ryPMWrTRW5ITVJ?
NCI-H520M{XhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPneXJQUUN3ME2yOE45QDZzIN88US=>MlzMV2FPT0WU
COLO-792MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTJ3LkK3N|Ih|ryPNEn2eYtUSU6JRWK=
NB12MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TZWWlEPTB;MkWuNlk1PyEQvF2=NETLflVUSU6JRWK=
GAKMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7EdXhHUUN3ME2yOU4zQTZ|IN88US=>MkHUV2FPT0WU
SW780MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnxTHQ3UUN3ME2yOU4{OjZ2IN88US=>M3POSXNCVkeHUh?=
GB-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnGN3VKSzVyPUK1MlQxPjlizszNMYTTRW5ITVJ?
P12-ICHIKAWANYXvW|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTJ3LkS3PFUh|ryPMlvZV2FPT0WU
NCI-H1651NHXHRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf4TWM2OD1{NT61PVch|ryPNIfVdYtUSU6JRWK=
KE-37NH;WWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJ3LkezNVUh|ryPNFnOXHlUSU6JRWK=
CCRF-CEMNV71fVRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDnd2VqUUN3ME2yOU46PjdizszNM3ezVXNCVkeHUh?=
SF295MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\HTWM2OD1{Nj6wOFI2KM7:TR?=MXLTRW5ITVJ?
G-361NEm4NW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH4dFJKSzVyPUK2MlExOjdizszNNF3KOWZUSU6JRWK=
HOP-92NX3VeIRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2mzWmlEPTB;Mk[uNVIzPiEQvF2=NH3MXnNUSU6JRWK=
UMC-11MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPZS5dEUUN3ME2yOk41PTF2IN88US=>NEjl[pdUSU6JRWK=
IST-SL1M2nicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofNTWM2OD1{Nj62OVkyKM7:TR?=M1u2eXNCVkeHUh?=
TE-11MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHr2Oo1KSzVyPUK2Mlc4PTJizszNM4i4[XNCVkeHUh?=
NCI-H1304NIDw[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlW3TWM2OD1{Nj65NVA5KM7:TR?=NF\QR29USU6JRWK=
SJSA-1NEXFW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlziTWM2OD1{Nz6wNVc3KM7:TR?=MWXTRW5ITVJ?
BCPAPNVGxZ|RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LJdmlEPTB;MkeuNVM4KM7:TR?=MorwV2FPT0WU
HTC-C3M2PYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDRVoxKSzVyPUK3MlI2PjFizszNM1;V[HNCVkeHUh?=
EW-16MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTJ5LkK5OFch|ryPNFS5TndUSU6JRWK=
HT-144MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrJVoFuUUN3ME2yO{41ODN{IN88US=>M2LEV3NCVkeHUh?=
MHH-ES-1M37xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTJ5LkS0OFch|ryPNVnuNoNbW0GQR1XS
T98GNGfRbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXYRYpKSzVyPUK3MlU5PDZizszNNGrR[otUSU6JRWK=
RPMI-8866NEjFTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTxTWM2OD1{Nz63OVYzKM7:TR?=NXvUTnBHW0GQR1XS
BENMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTSeoxGUUN3ME2yO{45PTF5IN88US=>NYHyfJZDW0GQR1XS
MDA-MB-231NF;tblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPHSWxKSzVyPUK4MlI4QTVizszNNV7YWm9rW0GQR1XS
HuH-7M3zwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jNRmlEPTB;MkiuOFAzQCEQvF2=M2HQbHNCVkeHUh?=
SK-N-FIMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTJ6LkSzN{DPxE1?M4fGOXNCVkeHUh?=
AN3-CANHvnWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HUd2lEPTB;MkiuOFM6PSEQvF2=M3HMVXNCVkeHUh?=
EGI-1MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2Lp[GlEPTB;MkiuOVkzQCEQvF2=NXjvRZFbW0GQR1XS
697NWnEXoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITpUFBKSzVyPUK4MlY{OzFizszNNHPG[FBUSU6JRWK=
TCCSUPNEXCN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HmXmlEPTB;MkiuOlQyQCEQvF2=MlX6V2FPT0WU
GR-STMnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEOxW2VKSzVyPUK4MlY3QTZizszNNWnOTVNGW0GQR1XS
SK-N-DZNX3RN5ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHT0OmVKSzVyPUK4MlY5QDVizszNM33lV3NCVkeHUh?=
MIA-PaCa-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3mdotKSzVyPUK4Mlc6PTlizszNNUi4XI1DW0GQR1XS
IGR-1Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJ6Lki4O|Qh|ryPMV7TRW5ITVJ?
BFTC-905M3f5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTJ7LkK3NFUh|ryPMYHTRW5ITVJ?
NCI-H1581NHz3Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTJ7LkOxOFUh|ryPMUPTRW5ITVJ?
RDNF7YUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fOemlEPTB;MkmuOVI{OyEQvF2=NEf0c|lUSU6JRWK=
SF268M3v5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJ7LkW5N|Eh|ryPNF2ySZFUSU6JRWK=
SHP-77MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHaTWM2OD1{OT62NVgzKM7:TR?=NH;2V2FUSU6JRWK=
D-566MGNF7wNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTGTWM2OD1{OT65N|k{KM7:TR?=NHXKT|lUSU6JRWK=
TGBC1TKBNIC5VWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofrTWM2OD1|MD6xNlM5KM7:TR?=M2e2cXNCVkeHUh?=
MEL-HOM4HNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX6yN2pnUUN3ME2zNE4yPDJ|IN88US=>MXfTRW5ITVJ?
SJRH30Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrjd5hPUUN3ME2zNE4zOTB6IN88US=>NGXwd4ZUSU6JRWK=
D-336MGM2fFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XzeWlEPTB;M{CuNlg6OiEQvF2=Mn;TV2FPT0WU
C3ANF32S5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnGXGcyUUN3ME2zNE4zQTJ5IN88US=>MoXCV2FPT0WU
Calu-6NF35[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlq0TWM2OD1|MD6yPVY{KM7:TR?=MV\TRW5ITVJ?
MZ1-PCMk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\Sb2lEPTB;M{CuN|k{KM7:TR?=NHnr[XNUSU6JRWK=
KYSE-70NYX1ZXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;yclZoUUN3ME2zNE42OTF2IN88US=>NV7vc5RxW0GQR1XS
CAPAN-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrQcoViUUN3ME2zNE42OThzIN88US=>M3nzb3NCVkeHUh?=
DK-MGMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1v4[mlEPTB;M{CuOVQ2PiEQvF2=NGjaWlJUSU6JRWK=
SK-HEP-1M2D4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEf5VJhKSzVyPUOwMlY{OjZizszNMn:1V2FPT0WU
MS-1M{fTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTNyLki4PFkh|ryPMX7TRW5ITVJ?
GI-ME-NMlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTNzLkC1O|Eh|ryPMlmzV2FPT0WU
NCI-H510ANYq4OHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjFbY5wUUN3ME2zNU41ODB4IN88US=>NGnmR2VUSU6JRWK=
NB17M4D6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XXfWlEPTB;M{GuOVE5PSEQvF2=MkC3V2FPT0WU
639-VNWnzOJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLQdmJKSzVyPUOxMlUzPDNizszNNFjEOohUSU6JRWK=
CAL-51MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFi2THJKSzVyPUOxMlU3PjdizszNNFn2WnZUSU6JRWK=
HGC-27MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PtU2lEPTB;M{GuOVg4OyEQvF2=M{j5SnNCVkeHUh?=
GOTOMnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTNzLki1NFYh|ryPMXHTRW5ITVJ?
ChaGo-K-1NYnaNJJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTN{LkCwO{DPxE1?MXjTRW5ITVJ?
RO82-W-1M{\udWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTN{LkG2NFQh|ryPNX3TeHlMW0GQR1XS
SH-4MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\zTWM2OD1|Mj6xPFU5KM7:TR?=MnvvV2FPT0WU
A204M131UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjPOlNoUUN3ME2zNk42ODZ7IN88US=>M1rBSHNCVkeHUh?=
DMS-273NVT5XlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLWTWM2OD1|Mj61N|IzKM7:TR?=MnfSV2FPT0WU
KGNMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mon1TWM2OD1|Mj62N|Mh|ryPNIfxXYNUSU6JRWK=
SK-MEL-2NFj4[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjSeWRKSzVyPUOyMlY2OjdizszNMnfBV2FPT0WU
NCI-H2228M1vZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nsUmlEPTB;M{KuOlYxOiEQvF2=NX\pNmJ1W0GQR1XS
MKN28NVnnPIJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nOUWlEPTB;M{KuO|g{QCEQvF2=NXLOZ5RkW0GQR1XS
H-EMC-SSM4PDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\VNHBKSzVyPUOyMlk3PzhizszNMWHTRW5ITVJ?
ATN-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7meWNYUUN3ME2zN{4yPDF4IN88US=>M2m5SHNCVkeHUh?=
D-263MGM3LlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUftfJlHUUN3ME2zN{45Ozd6IN88US=>NI\3R4xUSU6JRWK=
LU-135Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7zTHhKSzVyPUOzMlg5OjlizszNM1fvSXNCVkeHUh?=
C8166M{e5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTXeWhUUUN3ME2zN{45QDV2IN88US=>MWHTRW5ITVJ?
T-24MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfofWdZUUN3ME2zOE4xOjB3IN88US=>MnXqV2FPT0WU
MewoM1;VS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTN2LkGzOFkh|ryPMmHvV2FPT0WU
22RV1NGKxR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofpTWM2OD1|ND6xO|U1KM7:TR?=NV3qRohrW0GQR1XS
KM-H2MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\wTWM2OD1|ND6xO|c6KM7:TR?=MnXDV2FPT0WU
NCI-H2122MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjITWM2OD1|ND6zOFcyKM7:TR?=NGjYWJZUSU6JRWK=
ABC-1M2DKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\tb|BKUUN3ME2zOE4{Pjl|IN88US=>MljDV2FPT0WU
NCI-H1355NV7RNFhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDafnp3UUN3ME2zOE4{QDh7IN88US=>MXXTRW5ITVJ?
NOMO-1M3TTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlToTWM2OD1|ND61O|A{KM7:TR?=M3P4WnNCVkeHUh?=
MZ7-melMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7KcHdtUUN3ME2zOE43PDh5IN88US=>NUDZRWRCW0GQR1XS
NCI-H810M2PrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:xOJVKSzVyPUO0MlczPzhizszNNIH3UYpUSU6JRWK=
D-392MGMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\kdGlEPTB;M{WuNFU3PSEQvF2=NFS1eYRUSU6JRWK=
LB771-HNCMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDBTWM2OD1|NT6xOlU5KM7:TR?=M3\JSXNCVkeHUh?=
COLO-679NHTWT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTN3LkO4PEDPxE1?MmDjV2FPT0WU
SK-PN-DWMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHz5bnJKSzVyPUO1MlQ{PjlizszNMYDTRW5ITVJ?
VA-ES-BJNF\K[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHzfm5KSzVyPUO1MlQ3PDlizszNM4HwWXNCVkeHUh?=
KNS-42MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFi0ZopKSzVyPUO1MlU5OjZizszNMnq2V2FPT0WU
RVH-421M4X2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XifGlEPTB;M{WuO|Y1PSEQvF2=MYTTRW5ITVJ?
P30-OHKM1rGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHPfnpQUUN3ME2zOU45PzV{IN88US=>NF7O[FFUSU6JRWK=
G-402NIjEbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfZTWM2OD1|NT65PFY4KM7:TR?=M4jsWXNCVkeHUh?=
S-117NXHrZlVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnz2TWM2OD1|Nj6zNFA5KM7:TR?=MYXTRW5ITVJ?
RXF393NIrC[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYK5eXhJUUN3ME2zOk4{Pzh3IN88US=>NIfSZnFUSU6JRWK=
LCLC-103HM3LteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVi1UVduUUN3ME2zOk44QDB|IN88US=>NHnlTo5USU6JRWK=
U-118-MGM1jO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfkTWM2OD1|Nj64PFQ4KM7:TR?=NVXTPZRjW0GQR1XS
8-MG-BANFnyTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPuTWM2OD1|Nj65OFg{KM7:TR?=Mnn1V2FPT0WU
MFH-inoNGC4NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\IUWlEPTB;M{euN|M4OSEQvF2=M3;3PHNCVkeHUh?=
NCI-H23MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLhTWM2OD1|Nz60NVk3KM7:TR?=NV\mS|RqW0GQR1XS
NCI-H446MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmq1TWM2OD1|Nz60PFYzKM7:TR?=M4nnWnNCVkeHUh?=
LU-99AM4ewZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTN5LkW3N|Eh|ryPMmPVV2FPT0WU
KP-N-YNMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHiTWM2OD1|Nz62NVk2KM7:TR?=NW\oTpRKW0GQR1XS
SCC-9NUDkeWc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXoPZBZUUN3ME2zO{44QDN6IN88US=>MVLTRW5ITVJ?
EFM-19NEHIZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zzUWlEPTB;M{euO|k3PyEQvF2=MnzlV2FPT0WU
A427M2PMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTN5LkmxNFch|ryPNWDWeZExW0GQR1XS
LB831-BLCNHHXO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTN6Lk[wN|kh|ryPMkHrV2FPT0WU
HOSMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;ZZoI6UUN3ME2zPU43Ojd|IN88US=>NVOzUIF1W0GQR1XS
LAN-6M33xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTRyLkCxNVIh|ryPM4f4SnNCVkeHUh?=
U251MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mme4TWM2OD12MD60NFU1KM7:TR?=MkL2V2FPT0WU
SNU-387MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;mXIRKSzVyPUSwMlQ2PTNizszNNUGxenprW0GQR1XS
DMS-79M4jCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGr3O|FKSzVyPUSwMlU5QDlizszNNVm3ZlZ1W0GQR1XS
SK-LU-1M132dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3KPGI5UUN3ME20NE43PTZ6IN88US=>M{HBN3NCVkeHUh?=
HTM{fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvzOVVtUUN3ME20NE43PjN7IN88US=>NInmRXZUSU6JRWK=
KP-N-YSNYfsbYE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjUZoVjUUN3ME20NE43PzZ6IN88US=>NFfSOG9USU6JRWK=
DMS-114M3LyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NESwV5NKSzVyPUSwMlg{PzRizszNMorBV2FPT0WU
HUTU-80NGTseJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn75TWM2OD12MT6wOVY6KM7:TR?=MkfDV2FPT0WU
ONS-76MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYr4U21LUUN3ME20NU41PzB7IN88US=>MV\TRW5ITVJ?
A673M3OwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInOOW9KSzVyPUSxMlUyPTdizszNMYPTRW5ITVJ?
HPAF-IINHz2O21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTRzLk[3NFkh|ryPNFKzZnlUSU6JRWK=
UACC-257MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTRzLkezOlkh|ryPM1zENnNCVkeHUh?=
EW-22MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnflTWM2OD12MT64Olk4KM7:TR?=M{XGd3NCVkeHUh?=
NCI-H1755M{\keWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTRzLki3NlUh|ryPMXrTRW5ITVJ?
KYSE-150M4PLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DuVWlEPTB;NEKuNVc5OiEQvF2=M1zxUHNCVkeHUh?=
CGTH-W-1NXzOc5J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWraPJFqUUN3ME20Nk41QTV3IN88US=>M4XnNnNCVkeHUh?=
NB13MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XhT2lEPTB;NEKuOlIyPyEQvF2=MXHTRW5ITVJ?
SW872NXe2OYRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13SRmlEPTB;NEKuOlM{OSEQvF2=NIjMe5NUSU6JRWK=
KP-4NHXFcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLt[IIzUUN3ME20Nk45QDN{IN88US=>Mn7GV2FPT0WU
HCC38NUjibGRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVi2WlZRUUN3ME20Nk46PjF6IN88US=>NUfkZZJzW0GQR1XS
BB49-HNCNW\mZlV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjie|FKSzVyPUSzMlI{PTZizszNNHrlbWxUSU6JRWK=
CAL-62MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHvTWM2OD12Mz60NFI5KM7:TR?=M3rrWHNCVkeHUh?=
NCI-H2029NGnMfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUOwdZd2UUN3ME20N{42PThzIN88US=>MYnTRW5ITVJ?
M14MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LPZmlEPTB;NESuNVM{OiEQvF2=M3O5[3NCVkeHUh?=
COLO-680NNGfD[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTneGtZUUN3ME20OE4{OzlizszNMWfTRW5ITVJ?
Hs-578-TNF;LOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TDXGlEPTB;NEWuNFI6PCEQvF2=NYrmdZNzW0GQR1XS
MSTO-211HMn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTR3Lkm0PFIh|ryPNGryUINUSU6JRWK=
EW-1M3PoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\3cJJKSzVyPUS1Mlk3QDlizszNM2PKe3NCVkeHUh?=
SW948NXfJcodvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTR4LkS0OlIh|ryPNWL4VZh5W0GQR1XS
NCI-H460NGDpbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;1fIpDUUN3ME20Ok42OjNizszNMmPxV2FPT0WU
CAS-1NWLQ[5FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\rTWM2OD12Nj63O|AyKM7:TR?=M4PJOnNCVkeHUh?=
TGBC11TKBNUXoTlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTR5LkG3O|ch|ryPNHLMfmZUSU6JRWK=
HD-MY-ZMoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\zTWM2OD12OD63PFYh|ryPMnTZV2FPT0WU
NCI-H226M2T3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mof2TWM2OD12OT63O|g2KM7:TR?=NH3aRmdUSU6JRWK=
PA-1NFPGb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTWOngyUUN3ME20PU45OzN3IN88US=>NEPIOZhUSU6JRWK=
LB2518-MELNWjTfnZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTR7Lki3NlMh|ryPMnnvV2FPT0WU
A101DM4TZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPnTWM2OD12OT65OFI2KM7:TR?=NXPPT21lW0GQR1XS
NCI-H2087NUTvSYNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljNTWM2OD12OT65OlgzKM7:TR?=M36zUHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2
NCT02501603 Not yet recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University March 2016 Phase 2
NCT02629523 Not yet recruiting Lung Neoplasms|EGFR Gene Mutation Chonnam National University Hospital March 2016 Phase 2
NCT02695290 Recruiting Carcinoma, Non-Small-Cell Lung|ErbB Receptors Boehringer Ingelheim March 2016 Phase 4

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose+0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Customer Product Validation (3)


Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method CEER assay
Cell Lines H460/A549/RFU cell lines
Concentrations 0-10 μM
Incubation Time 4 h
Results This data showed that a potent dose-dependent inhibition of the HER1 and HER2 pathways in the HCC827 cells was observed by treatment with BIBW-2992. Other HER1 and/or HER2 pathway-activated cell lines, H1975 and H1650, were likewise had these pathway activations blocked by the treatment with BIBW-2992.

Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method Nikon inverted-phase microscope
Cell Lines lung tumor cell lines
Concentrations 0.1/1 µM
Incubation Time two weeks
Results Reduction of cell colony size formation was observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cells were grown in an anchorage-dependent manner.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Afatinib (BIBW2992) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 3 h
Results BIBW2992 treatment resulted in a reduction of EGFR phosphorylation in Breast cancer cells.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) ic50 | Afatinib (BIBW2992) price | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) solubility dmso | Afatinib (BIBW2992) purchase | Afatinib (BIBW2992) manufacturer | Afatinib (BIBW2992) research buy | Afatinib (BIBW2992) order | Afatinib (BIBW2992) mouse | Afatinib (BIBW2992) chemical structure | Afatinib (BIBW2992) mw | Afatinib (BIBW2992) molecular weight | Afatinib (BIBW2992) datasheet | Afatinib (BIBW2992) supplier | Afatinib (BIBW2992) in vitro | Afatinib (BIBW2992) cell line | Afatinib (BIBW2992) concentration | Afatinib (BIBW2992) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us